DOCSLIB.ORG

Guidelines for the Management of Acne Vulgaris

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for the Management of Acne Vulgaris South African Family Practice 2017; 59(1):24-29 S Afr Fam Pract Open Access article distributed under the terms of the ISSN 2078-6190 EISSN 2078-6204 Creative Commons License [CC BY-NC-ND 4.0] © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0 REVIEW Guidelines for the Management of Acne Vulgaris W Sinclair Head: Department of Dermatology, University of the Free State, Bloemfontein Corresponding author, email: [email protected] Abstract Background: Acne vulgaris is a very common skin condition that, in the vast majority, can and should be effectively managed by general medical practitioners. Several guideline documents for management thereof exist and there is an overwhelmingly large, confusing literature bank available on the topic. Methods: This article summarises and simplifies the main guideline documents that have been published over the last few years to present the results in an algorithmic approach to the treatment of the different types and grades of acne. Disclaimer: Adherence to these guidelines will not ensure successful treatment in every situation and should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed to obtaining the same results. Introduction Pathogenesis of acne vulgaris Acne vulgaris is the most common skin ailment in humans. It is Basic knowledge of the pathogenesis of acne is essential a chronic disease with potentially severe impact on the quality for practitioners, as treatment decisions have to be based on medication that will affect as many as possible of the of life of young people. Most cases are of mild severity and can factors involved. The more different pathogenetic factors are and should be managed by the general practitioner (GP). It is simultaneously addressed, the better the outcomes. On the therefore essential that GPs are well versed in the pathogenesis, other hand, two different drugs that address the same factors clinical diagnosis, grading of severity, treatment algorithm and will not have an additive effect. pharmacology of the medications used for acne. The below table outlines the relevant pathogenetic factors and The guidelines presented below are based on the latest the medications that will address each factor. documents generated by the Global Alliance for the Improvement There are numerous drugs that may worsen acne, mostly of Outcomes in Acne Treatment 20071 and 20092, as well as the hormonal preparations, and these should be discontinued as European Academy of Dermatology in 20123 and 2016.4 part of management. The most important ones are: Table 1. Main pathogenetic factors in acne and corresponding treatments Pathogenetic Factor Relevant Medication Androgen stimulation of sebaceous glands Cyproterone acetate; Drosperinone Hypersecretion of sebum Oral Isotretinoin Hyperkeratosis and occlusion of the duct that drains sebum into the hair Topical retinoids follicle The formation of the invisible microcomedo Topical retinoids Inflammatory mediators (Interleukin 1, etc.) released after stimulation of Topical retinoids; oral isotretinoin toll-like receptor 2 by Propionibacterium acnes Neutrophilic response to rupture of comedones and inflammation Oral cyclines; oral and topical dapsone; oral macrolides induced by free fatty acids in sebum Proliferation of P. acnes Oral cyclines; oral macrolides; topical benzoyl peroxide Inflammatory tissue damage by matrix metalloproteinases Oral cyclines www.tandfonline.com/oemd 24 The page number in the footer is not for bibliographic referencing Guidelines for the Management of Acne Vulgaris 25 • Progesterone containing contraceptives like intramuscular medroxyprogesterone acetate or norethisterone enanthate • Implantable progesterone (etonogestrel) pellets • Progesterone (levonorgestrel) releasing intra-uterine devices • Combination oral contraceptives that contain levonorgestrel as progestogen • Oral and topical corticosteroids • Anabolic steroids • Vitamin B12 (especially the high dose, intramuscular products) • Lithium • Diphenylhydantoin Other factors that worsen acne are mostly related to overhydrating the skin with (unnecessary) oily moisturising creams and masks. A skin suffering from acne does not require moisturising at all, unless some other pathology is also present. Picture 2: Inflammatory papules and small pustules Clinical diagnosis of acne vulgaris This is usually simple when basic rules are applied. It can present with varying numbers of open and closed comedones, inflammatory papules, pustules, nodules, cysts, ulcers and scars. The face is practically always involved, the back and chest frequently, the arms and thighs rarely. As a rule, comedones have to be present to be sure of the diagnosis, because there are several other conditions that may mimic acne, but their eruptions should not contain comedones. The only exception is acne induced by topical corticosteroids, which may show comedones, but it is not regarded as acne vulgaris. Conditions that feature in the differential diagnosis of acne vulgaris are: • Acne rosacea • Steroid induced acne • Bacterial folliculitis • Pseudofolliculitis barbae Picture 3: Pustules • Eosinophilic folliculitis • Demodiccidosis • Papulonecrotic tuberculid • Folliculotropic cutaneous T-cell lymphoma. Picture 1: Comedones Picture 4: Nodules and cysts www.tandfonline.com/oemd 25 The page number in the footer is not for bibliographic referencing 26 S Afr Fam Pract 2017;59(1):24-29 Grading of severity of acne vulgaris This is essential as it will be the major parameter that will determine treatment choice. Several grading systems for acne are propagated, mostly based on series of photographs on which the severity is graded rather subjectively. This does not have much practical value and should not be used for treatment decisions. Grading should be based on the types of lesions present, not on the number of lesions. For example: If only comedones are present, it is Grade 1 acne, even if there are 10 000 present; this will look very severe on a photograph, but the patient should still respond the same to topical retinoids as one with only 10 comedones and there will be no reason to use more potent or systemic treatment. Picture 5: Conglobate acne We thus propose the grading system in Table 2. It is easy to use, reproducible between observers and translates directly into treatment choices.5 Treatment algorithm for acne vulgaris4 Proposed treatment options for the different grades are as follows: Grade1: Drug of choice: Topical retinoids (adapalene, tretinoin or isotretinoin) Alternatives: Topical benzoyl peroxide; topical azelaic acid; comedo extraction for persistent, large comedones These preparations should be applied daily over the whole of the affected areas and treatment should continue even after Picture 6: Ulcerating acne (Acne fulminans) clearance. “Spot treatment” is ineffective. Grade 2: Method of choice: Topical retinoids plus antimicrobial preparations: - For superficial papules: Topical adapalene/benzoyl peroxide (BPO) combination product Alternatives: Topical retinoid at night, topical benzoyl peroxide in the morning; topical retinoid at night plus clindamycin/benzoyl peroxide combination product in the morning. Topical antibiotics should never be used alone! - For deep papules: Topical retinoid plus oral cyclines: Lymecycline, minocycline or doxycycline Alternatives: Topical retinoids plus oral contraceptives Picture 7: Folliculotropic cutaneous T-cell lymphoma resembling acne that contain cyproterone acetate or drosperinone (for women only). Table 2. Grading of acne severity Grade 1 Comedones only Grade 2 Comedones + red papules Grade 3 Comedones + red papules + pustules Grade 4 Comedones + red papules + pustules + nodules / cysts / conglobate lesions Acne fulminans The above + ulceration + fever and other systemic symptoms The presence of significant scarring places grading in the next higher category of severity. www.tandfonline.com/oemd 26 The page number in the footer is not for bibliographic referencing Guidelines for the Management of Acne Vulgaris 27 Topical retinoid plus oral macrolides for young patients can also be used, but such long-term use of topical antibiotics is or where unacceptable side-effects from cyclines were undesirable. found. Oral isotretinoin Topical retinoids plus dapsone as second line Present guidelines dictate strict indications for the use of this Systemic antibiotics should be used for a minimum of three drug. They are the following: months, but preferably not for longer than 4 months, to avoid • Grade 4 acne vulgaris the development of antibiotic resistance. During the fourth • Lesser grades of acne, that failed treatment with: month, topical benzoyl peroxide or zinc should be added as anti-resistance agents. • Topical retinoids plus 3 months of oral cyclines, or Topical retinoids plus 4 cycles of oral contraceptives containing There is no scientific rationale for using antibiotics (topical or cyproterone acetate or drosperinone; systemic) as monotherapy. • Lesser grades of acne with significant scarring, to prevent Grade 3: Method of choice: Topical retinoids plus oral cyclines further scarring; note that OIT does not remove scarring and as mentioned above can worsen scarring in some individuals; Alternatives: Topical retinoids plus combined oral • Dysmorphophobic patients who request the drug, especially contraceptives containing cyproterone acetate for when threatening self-harm; women. • Gram-negative folliculitis after prolonged antibiotic use. Topical
Load more

Recommended publications
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Disfiguring Ulcerative Neutrophilic Dermatosis Secondary To
    RESIDENT HIGHLIGHTS IN COLLABORATION WITH COSMETIC SURGERY FORUM Disfiguring Ulcerative Neutrophilic Dermatosis Secondary to Doxycycline and Isotretinoin in an Bahman Sotoodian, MD Top 10 Fellow and Resident Adolescent Boy With Grant Winner at the 8th Cosmetic Surgery Forum Acne Conglobata Bahman Sotoodian, MD; Paul Kuzel, MD, FRCPC; Alain Brassard, MD, FRCPC; Loretta Fiorillo, MD, FRCPC copy accompanied by systemic symptoms including fever and leuko- RESIDENT cytosis. We report a challenging case of a 13-year-old adolescent PEARL boy who acutely developed hundreds of ulcerative plaques as well • Doxycycline and isotretinoin have been widely used as systemicnot symptoms after being treated with doxycycline and for treatment of inflammatory and nodulocystic acne. isotretinoin for acne conglobata. He was treated with prednisone, Although outstanding results can be achieved, para- dapsone, and colchicine and had to switch to cyclosporine to doxical worsening of acne while starting these medi- achieve relief from his condition. cations has been described. In patients with severeDo Cutis. 2017;100:E23-E26. acne (ie, acne conglobata), initiation of doxycycline and especially isotretinoin at regular dosages as the sole treatment can impose devastating risks on the patient. These patients are best treated with a combi- cne fulminans is an uncommon and debilitating nation of low-dose isotretinoin (at the beginning) with disease that presents as an acute eruption of nodular a moderate dose of steroids, which should be gradu- A and ulcerative acne lesions with associated systemic ally tapered while the isotretinoin dose is increased to symptoms.1,2 Although its underlying pathophysiology is 0.5 to 1 mg/kg once daily.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • 1 EMA Tender EMA/2017/09/PE, Lot 2 Impact of EU Label
    EMA tender EMA/2017/09/PE, Lot 2 Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: risk awareness and adherence Protocol • Prof. Anna Birna Almarsdóttir, Professor in Social and Clinical Pharmacy at the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen • Prof. Marcel Bouvy, Professor of Pharmaceutical Care at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Rob Heerdink, Associate Professor at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Teresa Leonardo Alves, Researcher at the Centre for Health Protection, National Institute for Public Health and the Environment, The Netherlands. 1 Table of contents Background ...................................................................................................................... 3 Aims of the study ............................................................................................................. 4 Methods ........................................................................................................................... 4 Setting ........................................................................................... Error! Bookmark not defined. Study design ............................................................................................................................ 4 Population
    [Show full text]
  • Isotretinoin (Accutane) and Pregnancy
    Isotretinoin (Accutane®) This sheet talks about exposure to isotretinoin in a pregnancy or while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is isotretinoin? Isotretinoin is a prescription medication taken by mouth to treat severe cystic acne that has not responded to other treatments. Isotretinoin is a form of Vitamin A. It has been sold under brand names such as Accutane®, Absorica®, Amnesteem®, Claravis®, Epuris®, Clarus®, Myorisan®, Sotret®, and Zenatane®. How long after a woman stops taking isotretinoin should she wait to become pregnant? How long does isotretinoin stay in the body? It is recommended that a woman wait one month after stopping isotretinoin before trying to become pregnant. Usually, isotretinoin is no longer found in a woman’s blood 4-5 days after the last dose and most of its by-products should be gone within 10 days after the last dose. However, the time it takes isotretinoin to be cleared from the body can be longer in some people, which is why it is recommended to wait at least one month after stopping isotretinoin before trying to become pregnant. Can isotretinoin make it more difficult to get pregnant? Women who are trying to become pregnant should not be taking isotretinoin. There have been reports of irregular menstrual periods in some women taking isotretinoin. There are no reports of problems getting pregnant while taking isotretinoin. I just found out I am pregnant. Should I stop taking isotretinoin? Stop taking the medication right away. As soon as possible, call the healthcare provider who prescribed the isotretinoin and the healthcare provider who will be taking care of you during your pregnancy.
    [Show full text]
  • Isotretinoin for Neuroblastoma
    Isotretinoin for Neuroblastoma Isotretinoin (EYE so TRET in oin) is a form of vitamin A that is very concentrated. It can only be obtained by prescription. The oily liquid comes in a soft capsule. Brand names for this medicine are Amnesteem®, Absorica®, Claravis®, Myorisan® and Zenatane®. Isotretinoin is used to treat neuroblastoma, the most common type of cancer in children. This medicine is given along with other immunotherapy (cancer fighting) drugs during the active stage of illness. It may also be ordered to be taken during the maintenance phase of therapy. Usually isotretinoin is given after the child has received the medicine 131I- Metaiodobenzylguanidine (MIBG) and has had a Bone Marrow Transplant (BMT). Warnings If your child is allergic to retinoids, he should not take this medicine. When handling this drug, extreme care needs to be followed by women who are pregnant or breastfeeding. Isotretinoin can cause severe birth defects and can pass into breast milk. Someone else will need to give this medicine to your child. Because of the dangers of birth defects with isotretinoin, your child, your child’s doctor, and your pharmacy must register with the iPLEDGE™ program. To do this, go to www.ipledgeprogram.com. Failure to register means that your child will not get the medicine. When your child needs more medicine, the doctor will have to write a new prescription each time. How to give Isotretinoin can be given by mouth whole, buried in food whole, or dissolved and mixed with food. Always wear disposable gloves if there is a risk of touching the liquid inside the capsule.
    [Show full text]
  • Acitretin; Adapalene; Alitretinoin; Bexarotene; Isotretinoin
    8 February 2018 EMA/254364/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Assessment report Referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data Retinoids containing medicinal products INN: Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, Tazarotene Procedure number: EMEA/H/A-31/1446 Panretin EMEA/H/A-31/1446/C/000279/0037 Targretin EMEA/H/A-31/1446/C/000326/0043 Note: Assessment report as adopted by the PRAC and considered by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 5 2.3. Data on efficacy ..................................................................................................
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • NG198 Evidence Review F1
    FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Research recommendations for review question: For people with moderate to severe acne vulgaris what are the most effective treatment options? Research question - reduced dose oral isotretinoin What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why this is important Oral isotretinoin is prescribed by consultant dermatologist-led team for severe forms of acne resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy. The daily dose typically ranges between 0.5mg to 1mg/kg, however dosage adjustments may be required for people with severe intolerances or whom are at higher risk of developing serious adverse effects. There is limited high-quality data on the efficacy and optimum treatment duration of reduced (less than 0.5mg/kg) daily dose isotretinoin in acne. Furthermore, there have been reports of the successful use of reduced daily dose isotretinoin, including weekly (mini) or bi-weekly (micro) dosage regime as maintenance therapy in people with recurrent relapse despite adequate response to multiple courses of isotretinoin. The evidence for reduced dose isotretinoin as maintenance therapy have been limited to case series and small cohort studies. Further research will help to establish if • reduced daily dose of oral isotretinoin is effective in the treatment of acne vulgaris • reduced dose isotretinoin regime is effective as maintenance therapy; and • the optimum duration of treatment. Table 26: Research recommendation rationale Research question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why is this needed Importance to ‘patients’ or the The daily dose of isotretinoin prescribed usually ranges between population 0.5mg – 1mg/kg.
    [Show full text]
  • Acitretin; Adapalene; Alitretinoin; Bexarotene; Isotretinoin
    21 June 2018 EMA/261767/2018 Updated measures for pregnancy prevention during retinoid use Warning on possible risk of neuropsychiatric disorders also to be included for oral retinoids On 22 March 2018, the European Medicines Agency (EMA) completed its review of retinoid medicines, and confirmed that an update of measures for pregnancy prevention is needed. In addition, a warning on the possibility that neuropsychiatric disorders (such as depression, anxiety and mood changes) may occur will be included in the prescribing information for oral retinoids (those taken by mouth). Retinoids include the active substances acitretin, adapalene, alitretinoin, bexarotene, isotretinoin, tazarotene and tretinoin. They are taken by mouth or applied as creams or gels to treat several conditions mainly affecting the skin, including severe acne and psoriasis. Some retinoids are also used to treat certain forms of cancer. The review confirmed that oral retinoids can harm the unborn child and must not be used during pregnancy. In addition, the oral retinoids acitretin, alitretinoin and isotretinoin, which are used to treat conditions mainly affecting the skin, must be used in accordance with the conditions of a new pregnancy prevention programme by women able to have children. Topical retinoids (those applied to the skin) must also not be used during pregnancy, and by women planning to have a baby. More information is available below. Regarding the risk of neuropsychiatric disorders, the limitations of the available data did not allow to clearly establish whether this risk was due to the use of retinoids. However, considering that patients with severe skin conditions may be more vulnerable to neuropsychiatric disorders due to the nature of the disease, the prescribing information for oral retinoids will be updated to include a warning about this possible risk.
    [Show full text]
  • Oral Alitretinoin in Congenital Ichthyosis: a Pilot Study Shows Variable Effects and a Risk of Central Hypothyroidism
    Included in the theme issue: 256 Letters to the Editor ACNE, RETINOIDS AND LYMPHOMAS Acta Derm Venereol 2012; 92: 256–257 Oral Alitretinoin in Congenital Ichthyosis: A Pilot Study Shows Variable Effects and a Risk of Central Hypothyroidism Agneta Gånemo1, Mette Sommerlund2 and Anders Vahlquist3* 1Department of Dermatology, Institute of Clinical Research in Malmö, Lund University, Skåne University Hospital, Malmö, Sweden, 2Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark, and 3Department of Medical Sciences (Dermatology), Uppsala University, Uppsala, Sweden. E-mail: [email protected] Accepted October 20, 2011. Congenital ichthyosis is a large group of hereditary skin planned treatment period of 3 months. Clinical and laboratory disorders with different aetiologies, all of which are pre- evaluations were performed before the start of therapy and at monthly intervals, and consisted of physical examination, pho- sent at birth (1). The patients have dry, widespread scaling tography, interviewing the patients about effects and side-effects and thickened skin (2). At present there is no cure for of therapy, and blood sampling for analysis of haematological ichthyosis and therapy is mostly symptomatic. Life-long parameters, liver enzymes, creatinine, cholesterol, triglycerides, treatment with emollients is essential, and some patients thyroxin (T4) and tyroid-stimulating hormone (TSH) levels. also use systemic therapy with retinoids, especially aci- tretin (3). The most serious adverse effect of retinoids is RESULTS teratogenicity, which is a special concern for acitretin as it is excreted from the body slowly (3). All 4 patients completed the 3-month long trial, and two Alitretinoin (9-cis retinoic acid) is a fairly new oral of them (nos 1 and 3) wished to continue alitretinoin retinoid with more rapid clearance than acitretin.
    [Show full text]
  • FROM ACNE to RETINOIDS and LYMPHOMAS Composed by Anders Vahlquist, Editor-In-Chief
    ISSN 0001-5555 Volume 92 2012 No. 3 Theme Section A Non-profit International Journal for Skin Research, Clinical Dermatology and Sexually Transmitted Diseases Official Journal of - The International Forum for the Study of Itch - European Society for Dermatology and Psychiatry THEME ISSUE: FROM ACNE TO RETINOIDS AND LYMPHOMAS COMPOSED BY ANDERS VAHLQUIST, Editor-IN-CHIEF Acta Dermato-Venereologica www.medicaljournals.se/adv Acta Derm Venereol 2012; 92: 227–289 THEME ISSUE: FROM ACNE TO RETINOIDS AND LYMPHOMAS Composed by Anders Vahlquist, Editor-in-Chief This theme issue of Acta Dermato-Venereologica bridges two bexarotene exert positive and negative effects far beyond seemingly unrelated diseases, acne and lymphoma, by inclu- those of pure RAR agonists. For the former drug, this is il- ding papers on retinoid therapy for both conditions. Beginning lustrated in a large trial on chronic hand eczema (p. 251) and with acne vulgaris, accumulating evidence suggests that diet in a pilot study of its use for congenital ichthyosis (p. 256). after all plays a role, which is ventilated in a commentary (p. For bexarotene, a new Finnish study shows 10 years expe- 228) of a prospective study using low- and high-calorie diets rience of this therapy in severe cutaneous lymphoma (p. 258). in adolescents with acne (p. 241). Acne treatment regimes Depending on the stage of the disease, lymphomas can also usually differ from one country to another; a Korean survey be treated for instance with photodynamic therapy (p. 264) (p. 236) combined with a review on how to treat post-acne and methotrexate (p. 276).
    [Show full text]